Parkinson’s disease – Discover Pharma

Welcome to Discover Pharma! Today is : May 20, 2026

Parkinson’s disease

Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764
AC Immune has initiated a Phase 1 trial of its [...]

May 5, 2026
Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders
Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

May 5, 2026
Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
AC Immune interim Phase 2 data suggest ACI-7104.056 may slow Parkinson’s disease progression
AC Immune SA has reported positive interim results from [...]

May 5, 2026
Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Modulight Biotherapeutics raises $12 million seed funding for optogenetic therapy development
Modulight Biotherapeutics has raised $12.2 million in a Seed funding [...]

May 5, 2026
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics
Celon Pharma receives FDA clearance for Phase 3 trial of CPL’36 in schizophrenia
Celon Pharma S.A. has received FDA clearance to advance its [...]

May 5, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
NRG Therapeutics closes oversubscribed £50m series B to advance clinical data in Parkinson’s and proof of concept in ALS/MND
NRG Therapeutics Ltd, a neuroscience company developing treatments targeting mitochondrial [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK